Top Forbes SHOOK advisors pledge $1.5M to fund kidney cancer treatment at Sloan Kettering Cancer Center in New York ...

This case is part of a larger wave of litigation involving PFAS contamination against chemical manufacturers over the health ...

In an interview with Targeted Oncology, Jaime Merchan, MD, delved into data from the LITESPARK-013 trial evaluating ...

Jaime Merchan, MD, discusses the efficacy results observed in the LITESPARK-013 trial of belzutifan in patients with advanced clear cell renal cell carcinoma.

The CHMP's opinion is based on positive results from two late-stage studies on MRK's Welireg in two indications associated ...

EU regulators recommend approval of Merck's drug Welireg for certain patients with VHL disease or advanced kidney cancer.

Defective VHL protein is also present in most cases of advanced clear cell renal cell carcinoma (RCC), so a recommendation for belzutifan was issued to also cover this condition. The drug is indicated ...

In the expanding oncology market, Exelixis (EXEL) is gaining attention with its strong pipeline and impressive stock ...

Weill Cornell Medicine has received a four-year, $1.4 million grant from the U.S. Department of Defense to investigate a new therapeutic approach for ...

The program targets clear cell Renal Cell Carcinoma (ccRCC), a cancer with significant unmet ... IB-T101 has the potential to transform the treatment landscape for solid tumors, and we are eager to ...

Merck & Co.’s kidney cancer drug Welireg, Bayer and BridgeBio’s transthyretin amyloid cardiomyopathy (ATTR-CM) therapy ...